Higher-dose use of certain statins often best for cholesterol issues

October 15, 2012

(Medical Xpress)—A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.

But some statins work much better for this than others, the review concluded, and additional lipid-lowering medications added to a statin have far less value. And medications, of course, should be considered after first trying diet, weight loss and exercise.

The review, published in the Annals of Pharmacotherapy, examined the range of treatment options for "," or concerns about LDL that is too high; HDL cholesterol that is too low; elevated triglycerides; and other issues that affect millions of people around the world.

It concluded that use of statin drugs, which effectively lower LDL, or "bad" cholesterol, is appropriate for both moderate and high who have issues with their , or may already have experienced a or angina as a result of cardiovascular disease.

But it also found that in most cases simply increasing the statin dose would offer the best protection against serious , more so than using other drugs or combinations of drugs.

"Statins are proven medications that can reduce heart attacks and strokes by about 30 percent in the patients that need them," said Matt Ito, a professor of pharmacy practice at Oregon State University, author of the study and president-elect of the National Lipid Association.

"What we looked at here was whether adding other drugs or therapies to the use of statins could further reduce problems, and in most cases the research indicates that they didn't help," Ito said. "What did help was increasing the statin dose to higher levels within the range for which they are approved. And there did not appear to be a significant change in side effects based on any approved dosage."

The goal with what the researchers called "intensive monotherapy," or high doses of just one statin , was usually to reduce LDL cholesterol to 100 mg/dL or less – or 70 mg/dL or less for people who already have coronary disease, diabetes or other special risks. Failing that, the medication goal should be to at least cut the LDL level in half, Ito said.

For intensive monotherapy with an average patient, research indicates that only two of the most commonly prescribed statins are suitable: atorvastatin and rosuvastatin. Others that are "not suitable for intensive monotherapy," the review said, include fluvastatin, lovastatin, pitavastatin, pravastatin, and simvastatin.

All statin drugs, at lower dosages, can have value if less dramatic lowering of LDL levels is needed, the researchers said.

"The reaction to statin regimens varies with the individual, so some of these other drugs may also be able to accomplish the goals we're seeking," Ito said. "These recommendations are based on results with an average patient, but physicians may find some of their patients can do adequately well with other statins, or that they don't need intensive monotherapy."

Statin drugs are generally well tolerated but can be associated with some side effects, experts say, particularly myopathy, or muscle pain and damage. These are some of the factors considered in establishing safe and accepted dosages. Some of the available drugs at their highest accepted dosage have been shown to cut LDL levels more than others, Ito said, and are therefore the best candidates for intensive therapy.

Other medications sometimes given for dyslipidemia were shown to have less value or even pose additional risks, the review found. This includes fibrates to lower triglyceride levels; niacin to lower triglycerides and raise HDL levels; and omega-3 fatty acids that appeared safe, but added little in efficacy to what was already being accomplished with .

"We found that only in patients with extremely high and very low HDL would use of fibrates be appropriate to use in addition to statins," Ito said. "Otherwise the increased risks outweigh the benefits, especially in women."

Explore further: No proof fibrate drugs reduce heart risk in diabetes patients on statins

More information: More detail on some of these issues, Ito said, can be found online at the web site of the National Lipid Association, lipid.org. A link for consumers called "Learn your Lipids" would be especially helpful, he said.

Related Stories

No proof fibrate drugs reduce heart risk in diabetes patients on statins

August 10, 2011
Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of medications designed to lower their LDL or "bad" cholesterol and triglyceride levels while raising their HDL or "good" ...

Intensive cholesterol therapy with multiple drugs effective over long term

June 25, 2012
For the first time, a study has found that intensive cholesterol therapy involving a combination of drugs for 20 years may be more effective over the long run than taking a single statin medication.

New medication increases HDL cholesterol and decreases LDL cholesterol levels

November 15, 2011
Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated ...

Non-HDL-C level associated with risk of major cardiovascular events among patients taking statins

March 27, 2012
Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels ...

FDA adds new safety information to statin drugs

February 28, 2012
(AP) -- Federal health officials are adding new safety warnings about risks of memory loss and elevated blood sugar to statins, a widely prescribed group of cholesterol-lowering medications.

Recommended for you

Study links health risks to electromagnetic field exposure

December 13, 2017
A study of real-world exposure to non-ionizing radiation from magnetic fields in pregnant women found a significantly higher rate of miscarriage, providing new evidence regarding their potential health risks. The Kaiser Permanente ...

Increased air pollution linked to bad teenage behavior

December 13, 2017
A new study linking higher levels of air pollution to increased teenage delinquency is a reminder of the importance of clean air and the need for more foliage in urban spaces, a Keck School of Medicine of USC researcher said.

175 years on, study finds where you live still determines your life expectancy

December 13, 2017
Research led by the University of Liverpool has revisited a study carried out 175 years ago which compared the health and life expectancy of people in different parts of the country, including Liverpool, to see if its findings ...

Postmenopausal women should still steer clear of HRT: task force

December 12, 2017
(HealthDay)—Yet again, the nation's leading authority on preventive medicine says postmenopausal women should avoid hormone replacement therapy (HRT).

Will 'AI' be part of your health-care team?

December 12, 2017
(HealthDay)—Artificial intelligence is assuming a greater role in many walks of life, with research suggesting it may even help doctors diagnose disease.

State-level disclosure laws affect patients' eagerness to have their DNA tested

December 12, 2017
Different types of privacy laws in U.S. states produce markedly different effects on the willingness of patients to have genetic testing done, according to a new study co-authored by an MIT professor.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.